Anavex Life Sciences Corp (AVXL)

[Doc328]

On post-hoc analysis, CDR-COA was found to be one of the more sensitive measures in the large successful rivastigmine (Exelon-Novartis) Parkinson Dementia phase 3 study that led the FDA to award the additional indication for the drug to treat PDD. This was back in 2006 and it was approved for AD in US 2000. ADAS-Cog was the primary endpoint in the phase 3 study. This likely led to Lilly choosing CDR-COA as the primary endpoint, with ADAS-Cog and other measures as the secondary endpoints. Anavex just followed suit.

I posted about this endpoint in more detail so that everyone can put the A273 results in context upon release.